Emory University School of Medicine

AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study

Retrieved on: 
화요일, 11월 7, 2023
Ronald Reagan UCLA Medical Center, Hemofiltration, Anticoagulant, Dialysis, Nephrology, KOL, Emory University School of Medicine, Medication, Pharmaceutical industry

SAN MATEO, Calif., Nov. 7, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a virtual Key Opinion Leader (KOL) panel discussion on its lead candidate Niyad™ (nafamostat) for use as an anticoagulant in dialysis circuits. The panel will feature two thought-leaders in the nephrology and critical care fields who are also co-authors on a recent market research manuscript reporting current issues with anticoagulants in the dialysis circuit. The panel will also discuss the NEPHRO CRRT (Nafamostat Efficacy in Phase 3 Registrational Continuous Renal Replacement Therapy) Study, a registrational study comparing Niyad with placebo for dialysis circuit anticoagulation, which is planned to start in the fourth quarter. Both panel members are principal investigators in the trial.

Key Points: 
  • The panel will feature two thought-leaders in the nephrology and critical care fields who are also co-authors on a recent market research manuscript reporting current issues with anticoagulants in the dialysis circuit.
  • The panel will also discuss the NEPHRO CRRT (Nafamostat Efficacy in Phase 3 Registrational Continuous Renal Replacement Therapy) Study, a registrational study comparing Niyad with placebo for dialysis circuit anticoagulation, which is planned to start in the fourth quarter.
  • The webcasted event will take place on Wednesday, December 6, 2023 at 11:00 a.m.
  • A live question and answer will follow the discussion.

FDA Grants Breakthrough Device Status to Toku’s Patented Cardiovascular Risk AI (CLAiR) Platform

Retrieved on: 
목요일, 11월 2, 2023
Software, Professional Services, Pharmaceutical, Optical, Venture Capital, Technology, Medical Devices, Artificial Intelligence, Cardiology, Biotechnology, Medical Supplies, FDA, Health, Stanford University, Food, Genetics, Mortality, Breakthrough, Disease, Entrepreneurship, Regulation of tobacco by the U.S. Food and Drug Administration, Multimedia, CVD, American Heart, Risk, Hypertension, Health equity, Risk assessment, Pharmacy, Eye, Blood, AI, European Journal of Preventive Cardiology, MSEE, Patient, Emory University School of Medicine, Retina, Clair, Cardiovascular disease, Medical device, Medical imaging, Pharmaceutical industry, Ophthalmology, MD

Toku, Inc., a commercial medical device company specializing in imaging technology and AI, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its patented CLAiR technology.

Key Points: 
  • Toku, Inc., a commercial medical device company specializing in imaging technology and AI, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its patented CLAiR technology.
  • The CLAiR platform, if cleared by the FDA, will be the first medical device in the US market that can provide affordable, point-of-care and non-invasive evaluation for risk of cardiovascular disease (CVD) using fundus retinal images through a routine eye exam.
  • Working with its partners, Toku is aiming to establish the largest network for CVD risk assessment across the US and then globally.
  • View the full release here: https://www.businesswire.com/news/home/20231102799522/en/
    Toku's AI-powered CLAiR technology uses retina scans during regular eye exams to detect cardiovascular risk non-invasively.

Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023

Retrieved on: 
목요일, 11월 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, University of Leicester, Survival, FRCP, ALPN, GN, EGFR, Biomarker, Fig, Nephrology, PMN, MD, Inflammation, Cytokine, Doctor of Philosophy, Glomerular filtration rate, Immunoglobulin A, American Society of Nephrology, Multimedia, Society, BAFF, Glossary of education terms (G–L), Disease, Barratt, ASN, Webcast, Emory University School of Medicine, University, Immunoglobulin G, Autoimmunity, Glomerulonephritis, Patient, Infection, Vaccine, Sewage treatment, Pharmaceutical industry, Research, IgA nephropathy, Proteinuria, Alpine, Medicine, UPCR

RUBY-3 is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, where povetacicept is administered subcutaneously (SC) once every four weeks for up to 48 weeks.

Key Points: 
  • RUBY-3 is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, where povetacicept is administered subcutaneously (SC) once every four weeks for up to 48 weeks.
  • A higher dose of povetacicept, 240 mg SC every four weeks, continues to enroll, with initial data expected in 1H 2024.
  • A higher dose of povetacicept 240 mg every four weeks is currently being explored and will be of great interest.
  • “We eagerly await the initial data from the next 240 mg dose level in the first half of 2024.

Acadia Healthcare Welcomes Dr. Patrice A. Harris, MD, MA as Independent Director

Retrieved on: 
목요일, 10월 26, 2023
Mental Health, Other Health, Hospitals, Health, Managed Care, Grady EMS, MA, Digital health, Virginia University, West Virginia University, Health care, American Psychiatric Association, Committee, American Medical Association, APA, Patrice Harris, Entrepreneurship, Columbia University Vagelos College of Physicians and Surgeons, Morehouse School of Medicine, Multimedia, AMA, Legislation, Private practice, Behavioural sciences, Trustee, Growth, Physician, Substance abuse, Independent, Emory University School of Medicine, Acadia Healthcare, Outline of counseling, Public, African, California Community College Athletic Association, Mental health, Pharmaceutical industry, Nursing, Surgeon, MD, Psychiatry, Psychology, Medicine

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that Dr. Patrice A. Harris, MD, MA has been appointed to the Company’s Board of Directors effective October 26, 2023.

Key Points: 
  • Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that Dr. Patrice A. Harris, MD, MA has been appointed to the Company’s Board of Directors effective October 26, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20231026253607/en/
    Acadia Healthcare welcomes Dr. Patrice A. Harris, MD, MA as Independent Director (Photo: Business Wire)
    Dr. Harris is board-certified in psychiatry and has diverse experience as a private practicing physician, public health director and patient advocate.
  • Currently, Dr. Harris continues in private practice and is Co-Founder and Chief Executive Officer of eMed Digital Healthcare, a digital healthcare company she co-founded in 2020.
  • I am excited to be part of Acadia’s growth and the quality care it provides,” said Dr. Harris.

Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023

Retrieved on: 
금요일, 10월 13, 2023
Oncology, Medical Devices, Health, General Health, Pharmaceutical, Biotechnology, Emory University School of Medicine, IgA nephropathy, Autoimmunity, GN, ALPN, Society, ASN, Immunoglobulin A, American Society of Nephrology, Inflammation, Pharmaceutical industry, Medicine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present initial clinical data from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis including IgA nephropathy, in a late breaking poster presentation at the American Society of Nephrology (ASN) Kidney Week, November 1-5, 2023 in Philadelphia, Pennsylvania.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present initial clinical data from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis including IgA nephropathy, in a late breaking poster presentation at the American Society of Nephrology (ASN) Kidney Week, November 1-5, 2023 in Philadelphia, Pennsylvania.
  • Following the poster presentation, the Company will host an investor event after the close of the market.
  • Poster Title: Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoantibody-Associated Glomerulonephritis (GN)
    Presenter: James Tumlin, M.D., Professor of Medicine at Emory University School of Medicine, Founder and CEO of NephroNet Clinical Trials Consortium

Julie Zweig, MD, Integrative Sleep & ENT Is Now Offering Wellness And Health Coaching From Mimi Ellis PA-C, RDN, CHC.

Retrieved on: 
금요일, 10월 13, 2023
Food, Health, Multimedia, Knowledge, Emory University School of Medicine, National Society, Insulin resistance, Weight loss, MD, Self-control, Hearing, University, University of Pittsburgh Medical Center, Hormone, Otorhinolaryngology, RDN, Body image, Sleep, Overalls, General surgery, ENT, Suite, Patient, CHC, Nursing, Pharmaceutical industry, Atlanta metropolitan area

ALPHARETTA, Ga., Oct. 13, 2023 /PRNewswire-PRWeb/ -- Julie Zweig, MD, Integrative Sleep & ENT in Alpharetta, GA, is now offering wellness and health coaching from Mimi Ellis PA-C, RDN, CHC, a renowned registered dietitian and certified health coach. Ms. Ellis brings her extensive knowledge and experience to help patients achieve their wellness goals at Julie Zweig, MD Integrative Sleep & ENT where she teaches an intuitive eating / non-diet method to nutrition and has practiced this approach herself for over thirty years. With a focus on intuitive eating and developing a healthy relationship with food, in conjunction with lifestyle changes, patients can look forward to achieving sustainable results. Intuitive eating is a revolutionary method that focuses on listening to the body's natural cues and signals to guide eating habits for physical reliance rather than emotional eating. Her approach to nutrition is from a place of self-care, not self-control, and she doesn't believe in the restriction of food. She understands the challenges and frustrations of yo-yo dieting, weight struggles and body image obsession. One of the key areas where Ms. Ellis' guidance can make a significant impact is weight management. Using her unique approach, she can assist patients who are prescribed drugs for weight loss, as well as those using medications to address insulin resistance, such as Ozempic, Wegovy and Rybelsus, to achieve their desired goals and also maintain them after the use of these medications. Julie Zweig Integrative Sleep & ENT Clinic believes that continuing a healthy lifestyle is crucial, even after patients stop using weight loss drugs or insulin resistance medications. Ms. Ellis' guidance empowers patients to continue their journey towards improved health and wellness, ensuring the long-term benefits of these medications are sustained. Mimi Ellis started her healthcare career in 1993 as a registered dietitian, then continued to become a physician assistant (PA). She has been a practicing PA ever since, working in general surgery, ob/gyn and with Dr. Zweig in otolaryngology since 2013, and she also became a certified health coach in 2020 through the National Society of Health Coaches. Ms. Ellis offers a mix of online group courses, customizable digital meal plans, individual counseling, coaching and virtual sessions.

Key Points: 
  • Serving the Greater Atlanta, GA, area, Julie Zweig, MD Integrative Sleep & ENT promotes overall wellness and optimal health now with coaching from Mimi Ellis, PA-C, RDN, CHC.
  • ALPHARETTA, Ga., Oct. 13, 2023 /PRNewswire-PRWeb/ -- Julie Zweig, MD, Integrative Sleep & ENT in Alpharetta, GA, is now offering wellness and health coaching from Mimi Ellis PA-C, RDN, CHC , a renowned registered dietitian and certified health coach.
  • More about Julie Zweig, MD Integrative Sleep & ENT:
    Julie Zweig, MD Integrative Sleep & ENT is located at 2650 Holcomb Bridge Road, Suite 510 in Alpharetta, Georgia.
  • Dr. Julie Zweig, Julie Zweig, MD Integrative Sleep & ENT, 404-255-4080, [email protected] , https://juliezweigmd.com/
    View original content to download multimedia: https://www.prweb.com/releases/julie-zweig-md-integrative-sleep--ent-is-...

Georgia Research Alliance Trustees Name New President and CEO

Retrieved on: 
수요일, 9월 27, 2023
Emory University, Private sector, La Jolla Institute for Immunology, IBD, University, Cardiovascular disease, Infection, Cancer, Georgia State University, State government, Research, Biomedical sciences, Georgia Research Alliance, GRA, Student, Entrepreneurship, Retirement, Trustee, Interdisciplinarity, School, Economic development, Immunology, Inflammatory bowel disease, Emory University School of Medicine, Management, Pharmaceutical industry

Atlanta, GA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The Trustees of the Georgia Research Alliance voted today to appoint Timothy Denning, Ph.D., vice president for research and economic development at Georgia State University, as the fifth president and CEO of GRA.

Key Points: 
  • Atlanta, GA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The Trustees of the Georgia Research Alliance voted today to appoint Timothy Denning, Ph.D., vice president for research and economic development at Georgia State University, as the fifth president and CEO of GRA.
  • Denning, who will take the helm of the Alliance November 1, has led research and commercialization through a period of historic growth at Georgia State.
  • Denning’s leadership at Georgia State reflects a breadth and depth of activity that accelerated an already-growing research enterprise.
  • “A hallmark of GRA’s working model is forging strong collaborations to grow research and entrepreneurship at Georgia’s universities,” says GRA President and CEO Susan Shows.

Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer

Retrieved on: 
금요일, 9월 8, 2023
Health, Science, Research, Clinical Trials, Oncology, WCLC, Emory University, MDT, Emory University School of Medicine, ICI, Winship Cancer Institute, Hematology, Survival, Convention, OS, Case report, Lung cancer, International Association, NSCLC, TPS, National Primate Research Exhibition Hall, Patient, PD-L1, Conference, Pharmaceutical industry, Medical imaging, Hospital, Medicine

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9 – 13, 2023 in Singapore.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9 – 13, 2023 in Singapore.
  • Novocure will take part in presentations and symposia throughout the event and will exhibit several posters exploring the use of Tumor Treating Fields (TTFields) therapy in the treatment of lung cancer, including a new post-hoc analysis of data from its LUNAR trial in metastatic non-small cell lung cancer.
  • The LUNAR trial was designed to evaluate the use of TTFields therapy together with standard systemic therapies for the treatment of metastatic non-small cell lung cancer, following progression on or after platinum-based therapy.
  • “This analysis further elucidates the promising results from the LUNAR trial and the potential benefit of utilizing TTFields therapy for the treatment of metastatic non-small cell lung cancer,” Dr. Leal said.

New Online Tool Available to Help Health Care Providers Identify a Hard to Diagnose Breast Cancer

Retrieved on: 
화요일, 9월 12, 2023
IBC, Emory University School of Medicine, Mission, Breast, Research, Radiation therapy, Patient, Swelling, Biology, Diagnosis, Mastitis, MD Anderson Cancer Center, Red, Breast cancer, Dana–Farber Cancer Institute, Birth control, Medical imaging

DALLAS, Sept. 12, 2023 /PRNewswire/ -- A new diagnostic scoring system, developed by renowned breast cancer experts, is now available as an easy-to-use online tool through Susan G. Komen®, the world's leading breast cancer organization. This tool will help health care providers recognize and effectively diagnose a rare and aggressive breast cancer, inflammatory breast cancer.

Key Points: 
  • DALLAS, Sept. 12, 2023 /PRNewswire/ -- A new diagnostic scoring system, developed by renowned breast cancer experts, is now available as an easy-to-use online tool through Susan G. Komen®, the world's leading breast cancer organization.
  • This tool will help health care providers recognize and effectively diagnose a rare and aggressive breast cancer, inflammatory breast cancer.
  • The new Inflammatory Breast Cancer (IBC) Scoring System online tool is available at https://www.komen.org/ibc and may help to increase diagnostic accuracy, predict outcomes, guide treatment decisions and inclusion in clinical trials.
  • "The creation of this tool reflects the deep commitment of Komen, the Inflammatory Breast Cancer Research Foundation and the Milburn Foundation to accelerate progress in detecting and treating inflammatory breast cancer.

Groundbreaking Program Encourages Underrepresented Minorities to Consider Career in Neurosurgery

Retrieved on: 
금요일, 9월 8, 2023
Emory University School of Medicine, Harvard University, Spinal cord, State university system, Woman, Buffalo, Medicine, Brain, Hispanic and Latino Americans, Mount Sinai Beth Israel, CNS, Disorder, Sympathetic nervous system, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, Congress, Student, Congress of Neurological Surgeons, Neuroscience, Nervous system, Growth, Diagnosis, Pathway, Health, African Americans, Silviculture, Nursing, MD, Neurosurgery

WASHINGTON, Sept. 8, 2023 /PRNewswire/ -- Today, the Congress of Neurological Surgeons (CNS) Foundation launched its Pathway to Neurosurgery program in Washington, DC. The initiative is dedicated to alleviating health care disparities by encouraging high school students from underrepresented groups to pursue a career in neurosurgery or medicine.

Key Points: 
  • The initiative is dedicated to alleviating health care disparities by encouraging high school students from underrepresented groups to pursue a career in neurosurgery or medicine.
  • In recognition of this groundbreaking program, District of Columbia Mayor Muriel Bowser proclaimed Sept. 7-13 as Pathway to Neurosurgery Week.
  • Levy, MD, CNS president and professor and chair of neurosurgery at the State University of New York at Buffalo, stated, "The CNS is thrilled that Mayor Bowser has recognized the Pathway to Neurosurgery program.
  • "African Americans, Hispanic Americans and women are significantly underrepresented in neurosurgery, and the CNS Pathway to Neurosurgery program aims to address this problem by promoting diversity, equity and inclusion in neurosurgery.